

**LAP13 Rec'd PCT/PTO 15 FEB 2007**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Serial No: 10/565,183 (National Phase Filing under 35 U.S.C. § 371 for International Application No. PCT/EP2004/051522, filed July 16, 2004)

Applicant: VERMEIJ, P.

Confirmation No: 5236

Filed: to be assigned

Group Art Unit: 1653

Examiner: To be assigned

For: Hybrid Toxins Comprising Shiga-Like Toxin Subunits Fused to Escherichia Coli Heat Labile Enterotoxin Subunits and Vaccines Thereof

Attorney Docket: I-2003.006 US

February 13, 2007

**TRANSMITTAL LETTER FOR  
SUBSTITUTE SEQUENCE LISTING**

**Mail Stop: PCT**  
Commissioner of Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir/Madam:

Applicants submit herewith a Substitute Sequence Listing for inclusion in the captioned application.

Appl. No. 10/565,183  
National Phase of PCT/EP2004/051522  
Submission of Substitute Sequence Listing of February 13, 2007

***Amendments to the Specification***

Please insert the following section heading and paragraph on page 1, after the title:

**Reference to Sequence Listing**

The material saved on two identical compact discs (COPY 1 and COPY 2) under the file name "Substitute Sequence Listing," created on February 12, 2007, having a size of 13 KB is hereby incorporated by reference.

**Please replace the existing Sequence Listing with the Substitute Sequence Listing provided herewith.**

***Remarks***

I hereby state that the two compact discs are identical.

I hereby state that any amendments, made in accordance with 37 CFR 1.825(a), included in the substitute sheet(s) or compact disc(s) of the Sequence Listing are supported in the application, as originally filed. I hereby state that the substitute sheet(s) of the Sequence Listing does (do) not include new matter.

I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 CFR 1.825(b), is the same as the amended Sequence Listing.


Information for COPY 1 and COPY 2 of the compact discs is as follows:

Machine Format:	DELL-PC
Operating System Compatibility:	MS-Windows
Name of File on disc:	<b>Substitute Sequence Listing</b>
Size of File on disc:	<b>13 KB</b>
Date of File Creation:	<b>February 12, 2007</b>

Appl. No. 10/565,183  
National Phase of PCT/EP2004/051522  
Submission of Substitute Sequence Listing of February 13, 2007

Applicants do not believe that any other fee is due in connection with this filing. If, however, Applicants do owe any such fee(s), the Commissioner is hereby authorized to charge the fee(s) to Deposit Account No. **02-2334**. In addition, if there is ever any other fee deficiency or overpayment under 37 C.F.R. §1.16 or 1.17 in connection with this patent application, the Commissioner is hereby authorized to charge such deficiency or overpayment to Deposit Account No. **02-2334**.

Applicants submit that this application is in condition for allowance, and request that it be allowed. The Examiner is requested to call the Undersigned if any issues arise that can be addressed over the phone to expedite examination of this application.

Respectfully submitted,  
  
\_\_\_\_\_  
Aaron L. Schwartz  
Registration No: 48,181  
Attorney for Applicants

ALS:dap

Due: 2/14/07




## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov


U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/565,183	Paul Vermeij	I-2003.006 US

31846  
 INTERVET INC.  
 PATENT DEPARTMENT  
 PO BOX 318  
 MILLSBORO, DE 19966-0318



INTERNATIONAL APPLICATION NO.	
PCT/EP04/51522	
I.A. FILING DATE	PRIORITY DATE
07/16/2004	07/21/2003

CONFIRMATION NO. 5236  
 371 FORMALITIES LETTER



\*OC000000021576901\*

Date Mailed: 12/14/2006

## NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ [ebc@uspto.gov](mailto:ebc@uspto.gov)

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed

to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web.  
<https://sportal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html>

For more information about EFS-Web please call the USPTO Electronic Business Center at 1-866-217-9197 or visit our website at <http://www.uspto.gov/ebc>.

**If you are not using EFS-Web to submit your reply, you must include a copy of this notice.**

SHAKEEL AHMED

Telephone: (703) 308-9140 EXT 208

**PART 1 - ATTORNEY/APPLICANT COPY**

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/565,183	PCT/EP04/51522	I-2003.006 US


FORM PCT/DO/EO/922 (371 Formalities Notice)

## Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

**Mail Stop: PCT**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

on February 13, 2007  
Date

  
Signature

Diane Payne  
Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

**Serial No:** 10/565,183 (National Phase Filing under 35 U.S.C. § 371 for International Application No. PCT/EP2004/051522, filed July 16, 2004)  
**Applicant:** VERMEIJ, Paul  
**For:** Hybrid Toxins Comprising Shiga or Shiga-Like Toxin  
Subunits Fused to Escherichia Coli Heat Labile Enterotoxin  
Subunits and Vaccines Thereof  
**§ 371 File Date:** to be assigned  
**Confirmation No:** 5236  
**Group Art Unit:** 1653  
**Customer No.:** 31846  
**Attorney Docket:** I-2003.006 US

Receipt acknowledged of the following documents in the above-identified application:

Transmittal Letter for Substitute Sequence Listing (4 pages)  
Paper copy of Substitute Sequence Listing (6 pages)  
CRF Substitute Sequence Listing (2 cd's)  
Copy of Notification to Comply of 12/14/06 (2 pages)  
Self-addressed stamped post card (1)